potentially inappropriate medication in the elderly (no specific disease or condition necessary for study inclucion)
Conditions
Interventions
Group 1: The experimental intervention will consist of newly developed recommendations to avoid potentially inappropriate medication in the elderly on the basis of the PRISCUS list. The PRISCUS list w
Sponsors
Ruhr-Universität Bochum
Eligibility
Sex/Gender
All
Age
70 Years to No maximum
Inclusion criteria
Inclusion criteria: age = 70 years; at least 6 different drugs to take on a regular basis; life expectancy of at least 6 month at the discretion of the treating primary care physician; legal competence; willingness to comply with study arrangements (i.e. assessment in the primary care office, telephone interviews); accessibility by phone; written informed consent
Exclusion criteria
Exclusion criteria: cognitive impairment or overt dementia; missing legal competence; unwillingness to comply with study arrangements
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary analysis will be done on the office level to account for the cluster design. ANCOVA will be used to compare the proportion of patients per office with potentially inappropriate medication after 12 months of follow up. For the primary analysis, no difference will be made in the intervention group between the subgroups of intervention on physician level only and the involvement of the whole practice team. Potentially inappropriate medication will be defined as either at least one potentially inappropriate drug or at least one relevant drug-drug interaction or at least one inadequate dosage of a drug as defined by the PRISCUS list. The ANCOVA will account for the group assignment (intervention of control group) as a factor, and the proportion of patients per office with potentially inappropriate medication at baseline will be considered as a co-variate. All randomized offices will be analyzed according to the group assigned. Missing values in the potentially inappropriate medication variable during follow up will be replaced by the baseline value. | — |
Secondary
| Measure | Time frame |
|---|---|
| All secondary analyses will be explorative. As a secondary analysis, the subgroups in the intervention group (intervention on physician level only versus intervention on the practice team level) will be compared. The analysis will be done as already described for the primary endpoint. All further analyses will be done by method accounting for the cluster design. | — |
Countries
Germany
Contacts
Public ContactUlrich Thiem
Abteilung für Medizinische Informatik, Biometrie und Epidemiologie Ruhr-Universität Bochum
Outcome results
None listed